Migraine treatment throughout the lifecycle

Expert Review of Neurotherapeutics

Volumn 5, Issue 3, 2005, Pages 343-353

  Landy, Stephen H ^a   Lobo, Bob L ^b  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

Author keywords

Amitriptyline; Central sensitization; Dihydroergotamine; Isometheptene; Menstrual migraine; Metoclopramide; Migraine; Neurogenic inflammation; Propranolol; Sumatriptan

Indexed keywords

ACEBUTOLOL; ACETYLSALICYLIC ACID; ALMOTRIPTAN; AMITRIPTYLINE; ANALGESIC AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; BUTORPHANOL TARTRATE; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CELECOXIB; CHLORPROMAZINE; COCODAMOL; CYCLOOXYGENASE 2 INHIBITOR; DICHLORALPHENAZONE; DICLOFENAC; DIHYDROERGOTAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROPERIDOL; ELETRIPTAN; ERGOT ALKALOID; ESTROGEN; EXCEDRIN; FLUOXETINE; FROVATRIPTAN; GABAPENTIN; GESTAGEN; IBUPROFEN; ISOMETHEPTENE; KETOROLAC; METHYSERGIDE; METOCLOPRAMIDE; METOPROLOL; METOPROLOL TARTRATE; NADOLOL; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PINDOLOL; PROCHLORPERAZINE; PROPRANOLOL; PROTRIPTYLINE; RIZATRIPTAN; ROFECOXIB; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SEROTONIN UPTAKE INHIBITOR; STADOL NASAL SPRAY; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; TIMOLOL MALEATE; TOLFENAMIC ACID; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VENLAFAXINE; VERAPAMIL; ZOLMITRIPTAN;

ALLODYNIA; ALOPECIA; ASTHENIA; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; CONGENITAL MALFORMATION; DEPRESSION; DIAGNOSTIC APPROACH ROUTE; DIARRHEA; DIZZINESS; DROWSINESS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSAGE FORM; DRUG FATALITY; DRUG FORMULATION; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTRITIS; HALLUCINATION; HEART DISEASE; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; INSOMNIA; LANGUAGE DISABILITY; LIFE CYCLE; MEMORY DISORDER; META ANALYSIS; MIGRAINE; MYALGIA; NAUSEA; OBESITY; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PATHOPHYSIOLOGY; PEPTIC ULCER; QT PROLONGATION; REVIEW; SIDE EFFECT; SKIN TINGLING; SYSTEMATIC REVIEW; TASTE DISORDER; TORSADE DES POINTES; TREMOR; VASOCONSTRICTION; VOMITING; WEIGHT REDUCTION;

AGE FACTORS; AGING; ANALGESICS; CALCITONIN GENE-RELATED PEPTIDE; HUMANS; MIGRAINE DISORDERS;

EID: 18944402835     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.3.343     Document Type: Review

References (66)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41, 646-657 (2001).
2. Menken M, Munsat TL, Toole JF. The Global Burden of Disease Study: implications for neurology. Arch. Neurol. 57, 418-420 (2000).
3. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology 58, 885-894 (2002).
4. Gordon KE, Dooley JM, Wood EP. Prevalence of reported migraine headaches in Canadian adolescents. Can. J. Neurol. Sci. 31(3), 324-327 (2004).
5. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation (MAZE) survey. Headache 43, 19-26 (2003).
6. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8(Suppl. 7), 1-96 (1988).
7. Olesen J. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia 24(Suppl. 1), 1-160 (2004). Revised diagnostic criteria for headaches.
8. Schreiber CP, Hutchinson S, Webster CJ, Ames M, Richardson MS, Powers C. Prevalence of migraine in patients with a history of self-reported or physician-diagnosed "sinus" headache. Arch. Intern. Med. 164, 1769-1772 (2004).
9. Kaniecki RG. Migraine and tension-type headache. An assessment of challenges in diagnosis. Neurology 58(Suppl. 6), 15-20 (2002).
10. Patel NV, Bigal ME, Kolodner KB, Leotta C, Lafata JE, Lipton RB. Prevalence and impact of migraine and probable migraine in a health plan. Neurology 63, 1432-1438 (2004).
11. Lipton RB, Bigal ME, Steiner TJ, Silberstein SD, Olesen J. Classification of primary headaches. Neurology 63, 427-435 (2004).
12. Welch KMA. Contemporary concepts of migraine pathogenesis. Neurology 61 (Suppl. 4), 2-8 (2003). Excellent review of the pathophysiology of migraine.
13. Pappagalo M, Szabo Z, Esposito G, Lokesh A, Velez L. Imaging neurogenic inflammation in patients with migraine headaches. Neurology 52, 274-275 (2002).
14. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N. Engl. J. Med. 346(4), 257-270 (2002).
15. Landy S, Rice K, Lobo B. Central sensitisation and cutaneous allodynia in migraine: implications for treatment. CNS Drugs 18(6), 337-342 (2004).
16. 1B/1D receptor agonists. Proc. Natl Acad. Sci. USA 101, 4274-4279 (2004). Key article with important treatment implications.
17. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann. Neurol. 55, 19-26 (2004).
18. Ashkenazi A, Sholtzow M, Young WB. Prevalence of mechanical (brush) allodynia in migraine. Presented at the 56th Annual Meeting, San Francisco, CA, USA, P01.157 (2004).
19. Burstein R, Yarnitsky D, Goor-Aryeh I et al. An association between migraine and cutaneous allodynia. Ann. Neurol. 47, 614-624 (2000).
20. Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. Neurology 63, 848-852 (2004).
21. Cady RK, Sheftell F, Lipton RB et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin. Ther. 9, 1035-1048 (2000).
22. Hu XH, Raskin NH, Cowan R et al. Treatment of migraine with rizatriptan: when to take the medication. Headache 42, 16-20 (2002).
23. Scholpp J, Schellenberg R, Moeckesch B, Banik N. Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. Cephalalgia 24, 925-933 (2004).
24. Klapper J, Lucas C, Rosjo O, Charlesworth B. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia 24(11), 918-924 (2004).
25. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 42, 28-31 (2002).
26. Mathew NT, Kailasam J, Seifert T. Early treatment of migraine with rizatriptan: a placebo-controlled study. Presented at the 56th Annual Meeting, San Francisco, CA, USA, S21.005 (2004).
27. Winner P, Mannix LK, Putnam DG et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin. Proc. 78, 1214-1222 (2003).
28. Landy S, Savani N, Shackelford S, Loftus J, Jones M. Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int. J. Clin. Pract. 58, 913-919 (2004).
29. Carpay J, Schoenen J, Ahmad F, Kinrade F, Boswell D. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin. Ther. 2, 214-223 (2004).
30. Brandes JL, Roberson S, Hilliard B, Sikes C, Tiseo P. Early treatment of migraine: a prospective, double-blind, placebo-controlled trial of eletriptan in the early stages of attack. Presented at the 46th Annual Scientific Meeting of the American Headache Society, Vancouver, British Columbia, Canada, F41 (2004).
31. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358, 1668-1675 (2001).
32. Silberstein SD. Migraine. Lancet 363, 381-391 (2004).
33. Imitrex Injection. In: Physicians' Desk Reference. Thomson Healthcare 58th Edition. NJ, USA, 1519-1523 (2004).
34. Winner P, Adelman J, Aurora S, Ames M, Lener M. Pain-free results of sumatriptan 6 mg SC in the treatment of morning migraine: results from two prospective, randomized, double-blind, placebo-controlled studies. Presented at the 45th Annual Scientific Meeting of the American Headache Society, Chicago, IL, USA, F41 (2003).
35. Kaniecki RG. Mixing sumatriptan: a prospective study of stratified care using multiple formulations. Headache 41, 862-866 (2001).
36. Dahlof C. Clinical applications of new therapeutic deliveries in migraine. Neurology 61(Suppl. 4), 31-34 (2003).
37. Nappi G, Sandrini G, Sances G. Tolerability of the triptans: clinical implications. Drug Safety 26(2), 93-107 (2003).
38. 1B/1D) agonists in the acute treatment of migraine. Headache 44, 414-425 (2004).
39. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 43, 144-166 (2003).
40. Snow V, Weiss K, Wall EM, Mottur-Pilson C. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann. Intern. Med. 137(10), 840-847 (2002).
41. Evans RW, Atriham AR. QT prolongation with migraine medications. Headache 43, 809-810 (2003).
42. Romero CE, Baron JD, Knox AP, Hinchey JA, Ropper AH. Barbiturate withdrawal following internet purchase of fioricet. Arch. Neurol. 61(7), 1111-1112 (2004).
43. Freitag FG, Cady R, DiSerio F et al. Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. Headache 41(4), 391-398 (2001).
44. Landy S, Richardson M, O'Quinn S. Migraine, midrin, and imitrex. Headache 42, 322-323 (2002).
45. Evans RW, Loder E, Biondi DM. When can successful migraine prophylaxis be discontinued? Headache 44, 1040-1042 (2004).
46. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 22, 491-512 (2002). Thorough review of migraine prophylaxis.
47. Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin. Neurol. Neurosurgery 107, 44-48 (2004).
48. Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol. 61, 490-495 (2004).
49. Brandes JL, Saper JR, Diamond M et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 25 (291), 965-973 (2004).
50. Mathew NT, Rapoport A, Saper J et al. Efficacy of gabapentin in migraine prophylaxis. Headache 41, 119-128 (2001).
51. Tronvik E, Stovner LJ, Helde G et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289, 65-69 (2003).
52. Ruoff GE. Migraine: effective pharmacologic strategies for prevention and treatment. Headache Pain 14(2), 75-82 (2004).
53. Mukherjee DM, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286, 954-959 (2001).
54. Blumenfeld A. Botulinum toxin type A for the treatment of headache: pro. Headache 44, 825-830 (2004).
55. Welch KMA. Botulinum toxin type A for the treatment of headache: con. Headache 44, 831-833 (2004).
56. Evers S, Vollmer-Haase J, Schwang S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study. Cephalalgia 24(10), 838-843 (2004).
57. Troost BT. Botulinum toxin type A (Botox) in the treatment of migraine and other headaches. Expert Rev. Neurotherapeutics 4(1), 27-31 (2004).
58. Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S. Practice parameter, pharmacological treatment of migraine headache in children and adolescents. Neurology 63, 2215-2224 (2004). Evidence-based recommendations regarding migraine treatment in the pediatric population.
59. Brousseau DC, Duffy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. Ann. Emerg. Med. 43, 256-262 (2004).
60. Chutka DS, Takahashi PY, Hoel RW. Inappropriate medications for elderly patients. Mayo Clin. Proc. 79, 122-139 (2004).
61. Mannix LK. Management of menstrual migraine. Neurologist 9, 207-213 (2003).
62. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 63(2), 261-269 (2004).
63. Newman L, Mannix LK, Landy S et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 41, 248-256 (2001).
64. Loder E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drug 17(1), 1-7 (2003).
65. Durham PL. CGRP-receptor antagonists - a fresh approach to migraine therapy? N. Engl. J. Med. 350(11), 1073-1075 (2004).
66. Olesen J, Diener H-C, Husstedt IW et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350(11), 1104-1110 (2004).